

Company: Kikkoman Corporation
 Representative: Noriaki Horikiri,
 President and Chief Executive Officer
 Stock Code: 2801
 Stock Exchange: Tokyo, 1st Section
 For Inquiries to: Kazuki Usui,
 Corporate Officer General Manager
 Corporate Communication Department
 TEL: +81-3-5521-5811

Notice regarding correction of performance forecast

Based on the recent performance trend, we would like to inform you that we have corrected the performance forecast announced in April 27, 2016 as follows.

Correction of performance forecast

Correction of consolidated performance forecast in the second quarter (accumulated) of the fiscal year ending on March 31, 2017 (from April 1, 2016 to September 30, 2016)

(Millions of yen)

	Sales	Operating income	Ordinary income	Net income attributable to owners of parent	Net income in a quarter per share (JPY)
Previously announced performance forecast (A)	198,500	16,200	15,100	10,000	51.86
Corrected performance forecast this time (B)	198,500	16,200	14,600	14,500	75.20
Amount of increase (decrease) (B - A)	—	—	(500)	4,500	
Rate of increase (decrease) (%)	—	—	(3.3)	45.0	
(Reference) Performance results in the second quarter of the previous fiscal year (Second quarter of the fiscal year ending on March 31, 2016)	202,774	16,939	15,957	10,485	53.68

Correction of the full-year consolidated performance forecast ending on March 31, 2017 (from April 1, 2016 to March 31, 2017)

(Millions of yen)

	Sales	Operating income	Ordinary income	Net income attributable to owners of parent	Net income in the current year per share (JPY)
Previously announced performance forecast (A)	403,500	31,500	30,000	20,000	103.72
Corrected performance forecast this time (B)	403,500	31,500	29,000	24,000	124.47
Amount of increase (decrease) (B - A)	—	—	(1,000)	4,000	
Rate of increase (decrease) (%)	—	—	(3.3)	20.0	
(Reference) Results in the previous year (FY 2016)	408,372	32,598	31,029	19,964	102.67

Reason of correction

We informed you in "Notice regarding Tendering Shares of Riken Vitamin in its Tender Offer and Change in Scope of Consolidation" on April 27, 2016 that we had applied for the take-over bid of our own shares executed by Riken Vitamin Co., Ltd.(TSE 1st Section, code: 4526, hereinafter, "Riken"), which was our affiliated company accounted for by the equity-method. However, as a result of the application, the purchase of all the shares we applied for took effect by May 31, 2016. Consequently, Riken is not applicable as an affiliated company by the equity-method for our company any more.

Therefore we would like to correct the consolidated performance forecast in the second quarter consolidated accumulated period and full year for the sake of anticipating decreases, etc. in corporate tax and others due to decrease in return on investment by the equity method, and because the acquisition of the treasury shares of Riken through the take-over bid is applied as a reason of consent dividend.

*The above performance forecast is based on the information currently obtained and the assumption that it is determined reasonable and does not constitute a promise or guarantee that the company will achieve its numerical targets. In addition, actual performance results may significantly vary depending on various factors.